AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02584582 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liquid meal test
Study NCT02584582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liquid meal test
Study NCT02584582 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No drug (Baseline day)
Study NCT02985320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single-dose regimen of high dosage investigational sIPV
Description: The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
Study NCT02985320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single-dose regimen of medium dosage investigational sIPV
Description: The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
Study NCT02985320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three-dose regimen of high dosage investigational sIPV
Description: The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
Study NCT02985320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three-dose regimen of medium dosage investigational sIPV
Description: The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
Study NCT02985320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three-dose regimen of low dosage investigational sIPV
Description: The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
Study NCT02985320 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Three-dose regimen of commercialized sIPV
Description: The control vaccine was manufactured by Chinese Academy of Medical Sciences.
Study NCT02985320 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Three-dose regimen of commercialized IPV
Description: The control vaccine was manufactured by Sanofi Pasteur S.A (IMOVAX POLIO).
Study NCT02972866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
Study NCT00738582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-009 (Amatuximab)
Description: MORAb-009 (Amatuximab) by IV on Days 1 and 8 every 21 days for 6 cycles.
Study NCT00738582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
Study NCT00738582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
Study NCT02416817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Products only
Description: Based solely on massive transfusion triggers Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive blood products by prescription of the patient's anesthesiologist. The patient will be constantly observed and bleeding triggers will be reassessed hourly.
Study NCT02416817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of Care guided
Description: Based on massive transfusion triggers and thromboelastometry Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive the drugs guided by the results of the thromboelastometry. The dosis of each drug will be based on the analysis of the thromboelastometry curves (established algorithm).
Study NCT03718533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag was provided as 50 mg or 25 mg film-coated tablets for oral use administration
Study NCT03728322 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iHSCs treatment group
Description: iHSCs intravenous injection
Study NCT02312388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: catheter-over-the-needle technique
Description: using a 22 G Angiocath Plus™ catheter
Study NCT02312388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thin-wall needle technique
Description: using 18 - 21 G introducer needle
Study NCT02877979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS003 vaginal tablet
Description: The trial will be conducted in three cohorts of 12 women each. In each cohort, participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17. In each cohort, therefore, 9 participants will receive DS003 vaginal tablets and 3 participants will receive placebo vaginal tablets.
Study NCT02877979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04361188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MAC anesthesia
Description: Patients receives DBS under monitored anesthesia care.
Study NCT04361188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AAA anesthesia
Description: Patients receives DBS under asleep-awake-asleep anesthesia.
Study NCT00240045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine, albumin, octreotide LAR
Study NCT00240045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midodrine, octreotide, albumin
Description: midodrine up to 12.5 mg tid, octreotide LAR 20 mg im once, albumin 150 mg q weekly
Study NCT03371498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L
Study NCT03371498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone placebo
Description: Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L
Study NCT00813241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib reference formulation
Description: 200 mg single oral dose of celecoxib tablets
Study NCT00813241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib test formulation A1
Description: 150 mg single oral dose of celecoxib A1 formulation tablets
Study NCT00813241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib test formulation B2
Description: 150 mg single oral dose of celecoxib B2 formulation tablets
Study NCT00813241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib test formulation C1
Description: 150 mg single oral dose of celecoxib Cl formulation tablets
Study NCT00408317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrase® MT20
Description: Ultrase® MT 20 capsules containing enteric-coated minitablets orally daily at a dose stabilized during the first stabilization period (4 days), as per investigator's discretion, for 6 to 7 days in either first intervention period or second intervention period.
Study NCT00408317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to Ultrase® MT 20 capsules orally daily for 6 to 7 days in either first intervention period or second intervention period.
Study NCT01238068 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gamma nail stryker
Description: for acute unstable pertrochantric fractures the subjects will be treated randomaly with either Gamma nail device Vs Dynamic hip screw
Study NCT02317900 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TV005
Description: TV005 is a live attenuated recombinant tetravalent dengue virus vaccine. It will be administered as a 0.5 mL dose containing 10\^3 plaque forming units (PFUs) of each component (10\^3.3 PFUs/mL of rDEN1∆30, 10\^4.3 PFU/mL of rDEN2/4∆30(ME), 10\^3.3 PFU/mL of rDEN3∆30/31-7164 and 10\^3.3 PFU/mL of rDEN4∆30). It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
Study NCT02317900 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo vaccine will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
Study NCT02317900 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rDEN2∆30-7169
Description: rDEN2∆30-7169 is a live recombinant attenuated DENV-2 candidate vaccine virus. It will be administered as a 0.5 mL dose containing 10\^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
Study NCT02317900 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN2∆30-7169
Description: rDEN2∆30-7169 is a live recombinant attenuated DENV-2 candidate vaccine virus. It will be administered as a 0.5 mL dose containing 10\^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
Study NCT05972980 — intervention group
Intervention type: OTHER
Intervention: COVID-19
Description: The investigators stratified our population based on COVID-19 virus positivity to identify any risk factors in this population compared to the NON-COVID-19 population.
Study NCT02396199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents
Description: Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
Study NCT01213316 — intervention group
Intervention type: DRUG
Intervention: Raltegravir
Description: Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 48 or 144 weeks
Study NCT01213316 — intervention group
Intervention type: DRUG
Intervention: Raltegravir
Description: Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 96, 144, or 48 weeks
Study NCT02190695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: 20 mg/m2 by vein daily over 1 hour on Days 1-5 of each 28 day cycle.
Study NCT02190695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m2 by vein daily over 1 hour on Days 1-5 of each 28 day cycle.
Study NCT02190695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 by vein over 1 hour on Day 8 of each 28 day cycle.
Study NCT02190695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: 0.15 mg/kg by vein over 1 hour on Days 1-5 of each 28 day cycle.
Study NCT01774721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib (PF-00299804)
Description: Dacomitinib (PF-00299804) 45 mg tablets, continuous oral daily dosing.
Study NCT01774721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: Gefitinib 250 mg tablets, continuous oral daily dosing.
Study NCT04016935 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational
Study NCT00842335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JI-101
Description: JI-101, 50 mg capsules, will be administered daily for up to 112 days (four 28-day cycles); treatment may be extended if, in the opinion of the investigator, a patient has tolerated the treatment and appears to be benefitting from receiving study medication
Study NCT04336774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caption AI
Description: Software program that guides the investigator or any other non-sonographer to take the best possible pictures of the heart.
Study NCT00959855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Sixteen, two hourly pulmonary rehabilitation sessions over an eight week period. The first hour will consist of an individualized exercise programme based on exercise field tests. The second hour will consist of an educational component. A home exercise programme of inspiratory muscle training (Threshold(R)IMT (respiratory muscle trainer re:HS730EU-001 single patient use) starting between 15% -30% of PiMax and progress weekly to 60% for 30 mins a day/ 5 dats a week with an inspiratory/expiratory ratio of 3:4. Patients will also be encouraged to walk or undertake an home exercise programme based on a Borg score of between 3 and 5 an additional 3 days a week.
Study NCT02732574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oscilatory Positive Expiratory Pressure (OPEP) device
Description: OPEP devices will be set to the highest pressure setting tolerated on POD #1. If the highest pressure setting is not achieved on POD#1, the PT will increase the pressure daily with the aim to achieve the highest pressure setting as soon as tolerated by the patient or POD#3, whichever comes first. Patients will be instructed to complete 15 breaths in a seated position with the OPEP device twice per waking hour. This will occur in addition to usual care.
Study NCT02732574 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM Device Group
Description: SHAM devices will be provided to patients on POD #1 and set to the highest pressure setting externally, however no positive expiratory pressure will be provided as the internal pressure regulating mechanism has been removed. Patients will be instructed to complete 15 breaths in a seated position with the sham device twice per waking hour. This will occur in addition to usual care.
Study NCT03694353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegvaliase
Description: 40-60mg/day
Study NCT03806361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat grafts supplemented with ADRC
Description: Isolation of ADRC from fat aspirates and its use for supplementation of fat grafts.
Study NCT03806361 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Structural fat grafting
Description: Fat grafts without supplementation of ADRC
Study NCT03501849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polypectomy using a cold snare
Description: Polypectomy by cold-snare technique
Study NCT03633032 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Acquiring of ultrashort echo time (UTE) MRI sequences
Description: Modern MRI sequences (ultrashort echo time (UTE)) for a better depiction of bone anatomy
Study NCT02682524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pelubiprofen CR 45mg tab.
Study NCT02802826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Exercise Prescription
Description: The intervention is a walking- based exercise prescription with the aim of a graduated increase in exercise to achieve national guidelines (i.e. Over 150mins of moderate intensity exercise over a week).
Study NCT02679131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat will be administered once daily on days 1 to 5 of a 21-day cycle (up to 6 cycles) via 30-min. IV infusion.
Study NCT00760006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unasyn
Description: Subjects will receive the antibiotic or the saline placebo 30 minutes prior to the initial incision in their palatoplasty procedure. The FDA approved antibiotic used for this study is Unasyn. Unasyn is a first-line measure, used by ENT surgeons at Children's Hospital of Pittsburgh for antibiotic treatment of virtually all ear, nose and throat infections. The use of Unasyn for this study is off-label as with the majority of antibiotics used with children. Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm
Study NCT00760006 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm.
Study NCT00655291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP20B
Study NCT00655291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00640081 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Study NCT00640081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study NCT00640081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Study NCT00640081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00640081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Study NCT00640081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00640081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Study NCT00640081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00640081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Study NCT00640081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT00640081 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: immunohistochemistry staining method
Study NCT00640081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00640081 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Study NCT00640081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00180323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renewal
Description: Renewal is a CRT-D device for cardiac resynchronization therapy
Study NCT00665158 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UC (Usual Care Group)
Description: Usual Care Group - Treatment Implementation by Primary Care Physician
Study NCT00665158 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BI (Behavioral Intervention Group)
Description: Behavioral Intervention Group - Treatment Implementation by Health Educator
Study NCT01795664 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Functional Respiratory Imaging
Description: CT-scan of thorax, at visit 2 pre and postdose and at visit 3 pre and postdose
Study NCT01795664 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Functional Respiratory Imaging
Description: CT-scan of thorax, at visit 2 pre and postdose and at visit 3 pre and postdose
Study NCT01795664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate and Fluticasone propionate HFA pMDI
Description: Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg~At visit 2 or visit 3 (cross-over design)
Study NCT01795664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Evohaler
Description: Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg~At visit 2 or visit 3 (cross-over design)
Study NCT01795664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Test product
Description: Single dose of 2 puffs~To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day.
Study NCT01795664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Reference product
Description: Single dose of 2 puffs~To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day.
Study NCT02336750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: 125mg D1, 80mg D2-3
Study NCT02336750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: 15mg D2-4
Study NCT04446533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide and Hyaluronic acid filming formulation
Description: Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with BMG0703 by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of BMG0703 will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth).
Study NCT04446533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine 0.2%
Description: Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with Chlorhexidine 0.2% by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of Chlorhexidine 0.2% will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth).